Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODM-209
- Development stage
- Phase 2
- Lead developer
- Orion
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ODM-209 is an orally bioavailable, potent and selective small molecule inhibitor of cytochrome P450 side-chain cleavage enzyme (CYP11A1), also known as cholesterol side-chain cleavage enzyme. By inhibiting CYP11A1, it blocks the conversion of cholesterol to pregnenolone—the first and rate-limiting step in steroid hormone biosynthesis. This leads to suppression of steroid hormone production (including androgens and estrogens), which is relevant for the treatment of hormone-dependent cancers such as metastatic castration-resistant prostate cancer (mCRPC) and advanced breast cancer. Preclinical studies show that ODM-209 inhibits proliferation of hormone-positive tumor cells. The drug was developed by Orion and has been evaluated in phase 1/2 clinical trials for mCRPC and estrogen receptor-positive/HER2-negative advanced breast cancer[1][2][3][5][6].
- Other names
- ODM-209ODM209ODM 209
02
Targets
CYP11A1 (Cholesterol side chain cleavage enzyme)
Beyond the preview
Go deeper on ODM-209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODM-209.